

UNITED STATES PATENT APPLICATION

of

**CHRISTINE A. FRANKE, TOVÉ C. BOLKEN,
DENNIS E. HRUBY and KEVIN F. JONES**

for

**NEW INTERGENIC AND INTRAGENIC INTEGRATION SITES FOR
FOREIGN GENE EXPRESSION IN RECOMBINANT *S. GORDONII*
STRAINS**

**BURNS, DOANE, SWECKER & MATHIS, LLP
P.O. BOX 1404
ALEXANDRIA, VA 22313-1404**

**NEW INTERGENIC AND INTRAGENIC INTEGRATION SITES
FOR FOREIGN GENE EXPRESSION
IN RECOMBINANT *S. GORDONII* STRAINS**

[0001] U.S. Government Support

[0002] This work was supported in part by a grant from NIH (AI46176-01A1).

[0003] Continuing Application Data

[0004] This application is a continuation-in-part of PCT/US01/05493, filed February 22, 2001, which claims priority benefit of U.S. provisional application 60/184,645, filed February 24, 2000. The contents of these prior applications are hereby incorporated by reference herein.

[0005] BACKGROUND OF THE INVENTION

[0006] Field of the Invention

[0007] The present invention provides vectors for insertion of a heterologous DNA molecule into the genome of a gram-positive bacterium, such as the gram-positive commensal bacteria *Streptococcus gordonii*. Bacteria transformed with the vectors of the present invention will express the heterologous DNA, and can be used to produce the protein encoded by that DNA *in vitro* or *in vivo*.

[0008] Description of the Related Art

[0009] *Streptococcus gordonii* (*S. gordonii*) is a commensal bacteria of the human oral cavity. Recently, there has been a great deal of interest in engineering *S. gordonii* for use as a vaccine delivery vector. To that end, a large number of heterologous antigens have been expressed on the surface of *S. gordonii* (7, 9, 13) and these live recombinant bacteria have been shown to colonize the oral mucosa of recipient animals, inducing both a local and a systemic immune response (7).

[0010] Pozzi and coworkers made the initial *S. gordonii* chromosomal recombinants by randomly inserting the chloramphenicol transferase (cat) gene into the chromosome (11) and selecting the recombinant that showed the highest level of CAT activity. This recombinant then became the recipient parental strain and heterologous genes were inserted into the bacterial chromosome replacing the cat gene. Unfortunately, this method inserted genes into an unknown locus and rearranged the chromosome of wild type *S. gordonii* (3).

[0011] The following publications are representative of the state of the art

1. Bollet, C., et al. (1991) A simple method for the isolation of chromosomal DNA from Gram positive or acid-fast bacteria. *Nucl. Acids Res.* 19:1955.
2. Fischetti, V. A., et al. (1985) Size variation of the M protein in group A streptococci. *J. Exp. Med.* 161:1384-1401.
3. Franke, C. A., et al. (2001) Studies on the genomic organization of recombinant *Streptococcus gordonii* and development of a novel intergenic integration site for foreign gene expression. *J. Mol. Microbiol. Biotechnol.* 3: 545-555.
4. Jones, K. F., et al. (1986) Immunochemical localization and amino acid sequences of cross reactive epitopes within a streptococcal M6 protein. *J. Exp. Med.* 164:1226-1238.
5. Jones, K. F., et al. (1988). Spontaneous M6 protein size mutants of group A streptococci display variation in antigenic and opsonogenic epitopes. *Proc. Natl. Acad. Sci. USA.* 85:8271-8275.
6. Maniatis, T., et al. (1982). Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
7. Medaglini, D., et al. (1995). Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium *Streptococcus gordonii* after oral colonization. *Proc. Natl. Acad. Sci.* 92:6868-6872.
8. Payne, J., et al. (1996). Exploitation of a chromosomally integrated lactose operon for controlled gene expression in *Lactococcus lactis*. *FEMS Microbiol. Lett.* 136:19-24.
9. Pozzi, G., et al. (1992) Delivery and expression of heterologous antigen on the surface of streptococci. *Infect. Immun.* 60:1902-1907.

10. Pozzi, G., et al. (1990) Method and parameters for genetic transformation of *Streptococcus sanguis* Challis. *Res. Microbiol.* 141:659-670.
11. Pozzi, G., et al. (1988) Host-vector system for integration of recombinant DNA into chromosomes of transformable and non-transformable streptococci. *J. Bact.* 170:1969-1972.
12. Pozzi, G. and M. R. Oggioni. 1996. A host-vector system for heterologous gene expression in *Streptococcus gordonii*. *Gene.* 169:85-90.
13. Pozzi, G., et al. (1992). Expression of M6 protein gene of *Streptococcus pyogenes* in *Streptococcus gordonii* after chromosomal integration and transcriptional fusion. *Res. Microbiol.* 143:449-457.
14. Roe, B. A., et al. Streptococcal Genome Sequencing Project funded by USPHS/NIH grant #AI38406
15. Rosey, E. L. and G. C. Stewart. 1992. Nucleotide and deduced amino acid sequences of the lacR, lacABCD, and lacEF genes encoding the repressor, tagatose 6-phosphate genecluster, and sugar-specific PTS components of the lactose operon of *Streptococcus mutans*. *J. Bact.* 174:6159-6170.
16. Shiroza, T. and H. K. Kuramitsu. (1993). Construction of a model secretion system for oral streptococci. *Infect. Immun.* 61:3745-3755.
17. Siebert, P. D., et al. (1995). An improved PCR method for walking in uncloned genomic DNA. *Nucleic Acids Research.* 23: 1087-1088.
18. Simons, G., et al. (1993). Integration and Gene Replacement in the *Lactococcus lactis* lac Operon: Induction of a cryptic phospho- β -glucosidase in LacG-deficient strains. *J. Bact.* 175:5168-5175.
19. Sinha, R. P. 1991. Genetic characterization of partial lactose-fermenting revertants from lactose-negative mutants of lactococci. *Can. J. Microbiol.* 37:281-286.
20. Van Rooijen, R. J., et al. (1992). Characterization of the *Lactococcus lactis* lactose operon promoter: contribution of flanking sequences and LacR repressor to promoter activity. *J. Bact.* 174:2273-2280.
21. Bolken, T.C. et al. (2001). Identification of an intragenic integration site for foreign gene expression in recombinant *Streptococcus gordonii* strains. *App. Microbiol. Biotech. Appl. Microbiol. Biotechnol.* 55:192-197.

[0012] With the current interest in using commensal Gram-positive bacteria as vaccine delivery vectors, there is a need for additional clean, stable insertion sites that do not appreciably disrupt the bacterial chromosome. Furthermore, having multiple expression sites makes it possible to create a vaccine for more than one antigen, and/or to co-express an adjuvant with the antigen.

[0013] SUMMARY OF THE INVENTION

[0014] Briefly, the present invention provides stable insertion sites at distinct loci within the *S. gordonii* chromosome without genetically rearranging it or causing significant changes in the growth characteristics of the recombinant bacteria. Two such insertion sites were established. One is intergenic between two unknown open reading frames, orfA and orfB, downstream of the promoter that Pozzi et al. has previously used for protein expression(11). The second site is intragenic within the lacG gene, which is part of the lac operon. This second site is inducible by growth in media containing lactose.

[0015] With the foregoing and other objects, advantages and features of the invention that will become hereinafter apparent, the nature of the invention may be more clearly understood by reference to the following detailed description of the preferred embodiments of the invention and to the appended claims.

[0016] BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1. Integration of the M/aphIII cassette into the chromosome of *S. gordonii*. A NdeI site was introduced between orf A and orf B in pCR2.1:635 yielding p635(NdeI). The M/aphIII cassette has been inserted at the NdeI site between orf A and orf B in p635 (NdeI) yielding the recombinant plasmid p635:M/aphIII. V288 is the recipient *S. gordonii* strain. OrfA and orf B provided homologous sequence for recombination of p635:M/aphIII into the chromosome of V288 resulting in strain SP-02.

Primers CF43 and CF45 are located as shown.

[0018] Figure 2. (A) Partial sequence from the *lac* operon in *S. gordonii*. A walk upstream in the chromosome of V288 from the initial TB85-TB86 PCR product produced the 1733 bp CF6-TB86 product shown and this was cloned into pCR2.1 producing pCR2.1:6-86. Walking primers TB95, TB96 and TB100 are located as shown. pLacG was made by introducing a NdeI site at amino acids 94 and 95 in the *lacG* gene.

(B) The M/aphIII cassette was inserted at the NdeI site producing pLacG:M/aphIII. The predicted *lac* operon in *S. gordonii* is shown. The homologous *lacE/G* flanks around the M/aphIII cassette allowed for recombination into the chromosome resulting in strain SP-04. Primers TB107 and TB96 are located as shown.

[0019] Figure 3. Southern blot analysis depicting insertion of the M/aphIII cassette into 6-35 site.

(A) Schematic representation of the wild type V288 and mutant SP-02 chromosomes. The 6-36 and M/aphIII DNA probes are shown with dashed lines. The genomic DNA was digested with ClaI and SmaI.

(B) Southern blot of genomic DNA from V288 (lane 1) and SP-02 (lane 2) probed with 6-35 probe.

(C) Southern blot of M/aphIII DNA fragment (lane 3), V288 genomic DNA (lane 4) and SP-02 genomic DNA (lane 5) probed with M/aphIII probe.

[0020] Figure 4. Southern blot analysis depicting chromosomal insertion of the M/aphIII cassette into the *lacG* orf.

(A) Schematic representation of wild type V288 and mutant SP-04 chromosomes. The *lacG* and M/aphIII DNA probes are shown with dashed lines. The genomic DNA was digested with SmaI and XbaI.

(B) Southern blot of genomic DNA from V288 (lane 1) and SP-04 (lane 2) probed with *lacG* probe.

(C) Southern blot of M/aphIII DNA fragment (lane 3), V288 genomic DNA (lane 4) and SP-04 genomic DNA (lane 5) probed with M/aphIII probe.

[0021] Figure 5. Competition ELISA with M protein surface expressing

strains versus coli M6 protein. Each graph shows percent inhibition of binding of mAB 10F5 to coli M6 protein by decreasing concentrations of cells.

(A) Strains are shown as in the legend.

(B) Strains were grown in M17 broth supplemented with lactose (M17L) or glucose (M17G).

[0022] Figure 6. Results of chromosomal walks upstream and downstream of the GP1223 insert.

[0023] Figure 7. A: The alignment of the gram-positive promoter consensus with the sequence determined from "PCR walk 6-9" of the GP1223 insert.

B. A sequence containing dyad symmetry followed by a stretch of thymidine residues, approximately 150 nucleotides upstream of the -35 region, that conforms to a prokaryotic factor-independent RNA polymerase terminator sequence.

[0024] Figure 8. A: proposed structure of the 3057-bp *Cl*I fragment present as a single copy in GP204 and duplicated on either side of the M6 insertion site of GP1223.

B. Corroboration of this proposed genomic structure as demonstrated by Southern blot analyses.

[0025] Figure 9. A: Schematic representation of the transcription units predicted from the parental (GP204)) and recombinant (GP1223) *S. gordonii* strains. Location of promoters (P1, P2) and terminators (T1, T2, T3) are indicated relative to gene order. Predicted transcripts and sizes are indicated as dashed arrows above the maps. Probes (*1, *2) utilized in Northern analyses are localized by solid bars below the maps.

B: Northern blot analysis of total RNA purified from *S. gordonii* strains GP204 and GP1223. Probes utilized are indicated above the blots and the size (nt) of transcripts detected are indicated to the right of the blots.

[0026] DETAILED DESCRIPTION OF THE INVENTION

[0027] The present invention provides two new chromosomal integration sites for expression of foreign genes in gram positive bacteria, such as *Streptococcus gordonii* (*S. gordonii*). One integration site is intergenic between orfA and orfB in an operon of unknown function. The other site is intragenic within the lacG gene, which encodes phospho- β -galactosidase, and is part of the lactose (lac) operon. The emm6 gene from *Streptococcus pyogenes* was integrated in a stable configuration into the chromosome of *S. gordonii* at each of these integration sites, and in both cases the recombinant bacteria expressed the M6 protein on their surface.

[0028] Furthermore, expression from the lacG site within the lactose operon was shown to be regulated by growth on lactose. Identification of these new chromosomal insertion sites provides the ability to express multiple foreign genes from the same recombinant and the potential for modulating expression *in vitro* or *in vivo* by the use of a biosynthetic metabolite.

[0029] As noted above, several systems have been developed for expressing heterologous proteins in nonpathogenic oral streptococci, such as *S. gordonii* (9, 16). Pozzi and coworkers developed a chromosomal insertion site in *S. gordonii* for expressing protein (11). In making the genetically engineered streptococcal recipient strain, the chromosome has undergone some genetic rearrangement and duplication (3). The present study was undertaken to identify additional chromosomal insertion sites in the wild type *S. gordonii* genetic background for use without significant disruption of the chromosome that might have deleterious effects on the phenotype of derived recombinants which could compromise their eventual use as vaccines. The work done by Franke and Hruby (3) provides some insight into the promoter driving the recombinant genes and the surrounding area in the parental strain. We have taken advantage of this new genomic information to design plasmids that allow insertion of heterologous genes between orfA and orfB (Fig. 1). This allows for a clean and stable

chromosomal insertion site that does not disrupt any other loci. Protein expression from this locus was achieved; albeit at about a 7 fold lower level than insertion directly behind the promoter (Fig. 5A). Homology searches to identify this operon and promoter have not identified any known functions, but with further studies this operon may provide several other intergenic insertion sites that provide high levels of expression or that are possibly inducible.

[0030] Others have attempted to develop systems to express and over-express heterologous proteins in *L. lactis* (8, 18, 20). One well-studied pathway in *L. lactis* is the catabolism of lactose driven by the *lac* operon. This operon has a divergently transcribed repressor gene (*lacR*) upstream of the other *lac* genes (20). Expression of the *lac* genes has been shown to be induced by growth on lactose (8). Payne *et al* (8) inserted heterologous genes into the *lacG* orf, but the *lac* phenotype was not affected. The present inventors have now identified a portion of the *lac* operon in *S. gordonii* and express a heterologous gene inserted within the *lacG* orf. Protein expression levels from the *lacG* site were lower than expression from the intergenic "635" site (Fig. 5A), but clearly inducible by the presence of lactose in the growth media (Fig. 5B). This provides a second clean and stable insertion site that can be regulated simply by lactose concentration. Further studies would need to be done to see how controllable this system is and to what level, both *in vitro* and *in vivo*. This may be of particular importance when using the gram-positive protein expression system, SPEX, to express proteins *in vitro* whose activity may be deleterious to bacterial growth (e.g. proteases). Likewise the ability to induce foreign gene expression on demand may provide a mechanism for pulsed delivery of antigen to the immune system to maximize the protective immune response without induction of tolerance.

[0031] Preferred insertion sites (restriction enzyme sites) for use in the present invention include NdeI, BamHI, BglII, ClaI, EcoRI, EcoRV, HindIII, HpaI, KpnI, PvuII, PstI, SacI, SalI, Scal, SpeI, SphI, StuI, XbaI, and XhoI.

Preferred selectable markers for use in the present invention will confer antibiotic resistance, e.g., resistance to kanamycin, erythromycin, spectinomycin, and/or tetracycline. Particularly preferred selectable markers include the kanamycin resistance gene aphIII, the erythromycin resistance genes ermC, and ermAM, the spectinomycin resistance gene aadA, and the tetracycline resistance genes tetM and tetO.

[0032] The constructs of the present invention are useful for introducing heterologous genes into any gram-positive bacterium. Suitable gram-positive bacteria include *Streptococcus gordonii*, *Streptococcus pyogenes*, *Streptococcus mutans*, *Streptococcus epidermidis*, *Streptococcus pneumoniae*, *Lactococcus lactis*, *Lactobacillus helveticus*, *Lactobacillus paracasei*, *Enterococcus faecalis*, *Staphylococcus aureus*, Group B streptococci, Group G streptococci, *Peptostreptococcus magnus*, *Streptococcus dysgalactiae*, *Streptococcus suis*, *Streptococcus sobrinus*, *Listeria monocytogenes*, *Actinomyces viscosus*, *Actinomyces naeslundii*, *Streptococcus zooepidemicus*, *Streptococcus equisimilis*, *Streptococcus sobrinus*, *Bacillus licheniformis*, *Streptococcus sanguis*, and *Streptococcus salivarius*.

[0033] The following examples are presented in order to more fully illustrate the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

[0034] EXAMPLE 1

[0035] Materials and Methods

[0036] Bacteriological methods. Strains, plasmids, and primers used in this Example are listed in Table 1.

[0037] TABLE 1. Bacterial strains, plasmids and oligonucleotides

Strain, plasmid or oligo	Relevant markers and characteristics	Reference or source
Strains		
<i>E. coli</i>		
INVαF	F <i>endA1 recA1 hsdR17</i> (r _k ⁻ , m _k ⁺) <i>supE44 thi-1 gyrA96 relA1</i> Ö80 <i>lacZ</i> ÄM15 Ä(<i>lacZYA-argF</i>)U169	Invitrogen
XL1 Blue	<i>recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac</i> [F <i>proAB lacI</i> ªZÄM15 Tn10 (Tet ^r)] ^c	Stratagene
<i>S. gordonii</i>		
V288	Wild Type (ATCC 35105)	ATCC
GP1223	M protein recombinant strain that expresses M6 protein (<i>S. pyogenes</i>) residues 1 to 16 fused to residues 222-441 and contains an <i>aphIII</i> gene, Km ^r	G. Pozzi
SP-02	M protein recombinant strain, p635:M/ <i>aphIII</i> in V288, Km ^r	This work
SP-04	M protein recombinant strain, pLacG:M/ <i>aphIII</i> in V288, Km ^r	This work
635/ermC	M protein recombinant strain, p635/ermC in V288, Em ^r	This work
LacG/ermC	M protein recombinant strain, pLacG/ermC in V288, Em ^r	This work
Plasmids		
pCR2.1	Km ^r , Amp ^r	Invitrogen
pCR2.1:635	1.1-kb PCR-amplified 6-35 walk from V288 cloned into pCR2.1 at EcoRI, Amp ^r	This work
p635(NdeI)	NdeI site incorporated in between orf 1 and orf 2 in pCR2.1:635, Amp ^r	This work
pCR2.1:6-86	1733 bp PCR amplified 6-86 walk containing most of the <i>lacG</i> gene and part of the <i>lacE</i> gene from V288 cloned into pCR2.1 at EcoRI, Amp ^r	This work
pLacG	Derivative of pCR2.1 carrying 1.7-kb <i>lacE/G</i> cassette with NdeI incorporated within the <i>lacG</i> ORF, Amp ^r	This work
p635(NdeI) derivatives		This work
p635/ermC	1.2-kb <i>ermC</i> fragment from pSMB104 cloned into NdeI site, Amp ^r	This work
p635:M/ <i>aphIII</i>	2.7-kb M/ <i>aphIII</i> fragment from GP1223 cloned into NdeI site, Amp ^r	This work
pLacG derivatives		
pLacG/ermC	1.2-kb <i>ermC</i> fragment from pSMB104 cloned into NdeI site, Amp ^r	This work

Strain, plasmid or oligo	Relevant markers and characteristics	Reference or source
pLacG:M/aphIII	2.7-kb M/aphIII fragment from GP1223 cloned into NdeI site, Amp ^r	This work
Oligonucleotides		
CF4	5' -AATAGGGCTCGAGCGGC- 3'	23
CF5	5' -GGATCCTAATACGACTCACTATAGGGC- 3'	23
CF6	5' -AATAGGGCTCGAGCGGC- 3'	23
CF7	5' -ACCTGCCC-(c3-lcaa-CPG spacer)	3
CF35	5' -CGATTCGACATAGAAATAAATTGGAG- 3'	3
CF43	5' -GTTTGGTGACCTATAGTCAGTG- 3'	3
CF45	5' -TGGATGGCATGAATGTATAGAT- 3'	3
TB59	5'-AAAGAAGCATAACATATGTCAAAACAAG-3'	This work
TB85	5' -ACACTTCATCACTTTGATACCCCAGA- 3'	This work
TB86	5'-CCATTTGACCATGAGAAGACATCCATC-3'	This work
TB95	5'-AAATCTCCATTTGAATGAAGTGCCTCTGGGG-3'	This work
TB96	5'-GTCCACAAAGTGCTCAATATTATCCCGATTGAG-3'	This work
TB100	5'-AGGGCGTCAGAGAATCTCCAACCCATATAACC- 3'	This work
TB103	5'-GGAATTCCATATGCGGATAATAAATATATATAAACG-3'	This work
TB104	5'-GGAATTCCATATGCGATTACAAAAAATAGGCACACG3'	This work
TB107	5'-GCAGGAGTGGACGAAGAAGCTCC-3'	This work
TB117	5'-GGATCCCATATGTAAGGAGCATAAAAATGGC-3'	This work

Escherichia coli strains were grown in Luria-Bertani broth or on Luria-Bertani medium containing 1.5% agar. *S. gordonii* was plated on or cultured in Brain-Heart infusion (BHI, Difco) with or without 1.5 % agar respectively. M17 (Difco) supplemented with 2% glucose (M17G) or 2 % lactose (M17L) was also used for culturing *S. gordonii* stains for the induction experiments. Ampicillin was added at 50 µg/ml for *E. coli*, erythromycin was used at 5 µg/ml and kanamycin was used at 500 µg/ml for *S. gordonii*. Frozen cells of naturally competent *S. gordonii* V288 were prepared and transformed as previously described (10). Standard procedures were used for gene fusions and mutagenesis in *E. coli* vectors (6). Chromosomal DNA from *S. gordonii* strains was prepared as described previously (1).

[0038] Construction of 635 insertional mutants. An 1153 bp DNA fragment consisting of orf A and orf B, was amplified by PCR with primers CF6 and CF35. The amplified product was purified and cloned into pCR2.1-

TOPO vector to yield the plasmid pCR2.1:635. A NdeI site was created, with primer TB59, between orf A and orf B in pCR2.1:635 using the Quick ChangeTM site directed mutagenesis kit (Stratagene) yielding p635(NdeI) (Fig. 1). The erythromycin gene from pSMB104 was amplified using primers TB103 and TB104 and inserted into the NdeI site of p635(NdeI) yielding p635/ermC. *S. gordonii* V288 were transformed with p635/ermC and generated erythromycin resistant strain 635/ermC. A 2.7 Kb M/aphIII fragment, containing the *emm6* gene (12) fused to the *aphIII* gene, was amplified from *S. gordonii* GP1223 with primers TB117 and TB104. The amplified product was purified and digested with NdeI and cloned into the NdeI site in p635(NdeI) yielding p635:M/aphIII (Fig. 1). Competent cells of *S. gordonii* V288 were transformed with p635:M/aphIII and generated kanamycin resistant strain SP-02 (Fig. 1). 635/ermC and SP-02 were verified by PCR analysis across the plasmid-chromosome junction with the primer pair CF43 and CF45 and by southern blot analysis.

[0039] Construction of LacG knockout mutants. The *lac* operon sequence from *S. mutans* (15) was used to run a homology search against the *S. pyogenes* sequence database (14). Primers TB85 and TB86 were designed based on the highly conserved regions within the *lacG* orf. A 958 bp *lacG* fragment was PCR amplified using TB85 and TB86 from chromosomal DNA prepared from SP204(1-1) (Fig. 2A). DNA upstream and downstream of this 958 bp region was cloned by chromosomal walking as described previously (17). Briefly, chromosomal DNA from V288 was digested with EcoRV, PvuII or ScaI and ligated with adaptor primers CF4 and CF7. This adaptor ligated DNA was used as template for PCR using adaptor primers (CF5 and CF6) and gene specific primers (TB95, TB96 and TB100) (Fig. 2A). This previously unpublished sequence from the *lac* operon in *S. gordonii* was submitted to GenBank (Accession No. AF210773). A cloned 1733 bp region containing most of the *lacG* gene and part of the *lacE* gene in pCR2.1:6-86 (Fig. 2A) was mutagenized by site directed mutagenesis (Stratagene) and a NdeI site was introduced within the *lacG* orf

between amino acids 94 and 95 yielding pLacG. The erythromycin gene from pSMB104 was inserted into the NdeI site in pLacG yielding pLacG/ermC. *S. gordonii* V288 was transformed with pLacG/ermC and generated the erythromycin resistant knockout strain LacG/ermC. A 2.7 kb M/aphIII fragment was amplified from *S. gordonii* GP1223 with primers TB117 and TB104. The amplified product was purified and digested with NdeI and cloned into the NdeI site in pLacG yielding pLacG:M/aphIII (Fig. 2B). Competent cells of *S. gordonii* V288 were transformed with pLacG:M/aphIII and generated erythromycin resistant strain SP-04 (Fig. 2B). LacG/ermC and SP-04 were verified by PCR analysis across the plasmid-chromosome junction with the primer pair TB107 and TB96 and by southern blot analysis.

[0040] Immunological assays.

[0041] Streak blot analysis. *S. gordonii* transformants were streaked on the surface of BHI plates by toothpick transfer of colonies from the selection plates. Each plate contained the transformants, an M6+ strain (GP1223) and an M6- strain (V288) for controls. Streak blot was performed as previously described (9), using monoclonal antibody (mAb) 10F5 (2), raised against the recombinant M6 protein purified from *E. coli*.

[0042] Western blot analysis. The streptococcal strains were grown to late stationary phase in BHI. 300 µl of culture was pelleted by centrifugation in 1.5ml microfuge tubes. The culture supernatant was acetone-precipitated and the pellet was resuspended in SDS sample buffer. The samples were run on a 4-12% Bis-Tris gel and transferred to a Millipore Immobilon-P transfer membrane. Western blotting was performed as previously described (2) using mAb 10F5.

[0043] Competition ELISA. Streptococcal overnight cultures were back-diluted 1:100 in BHI (M17G and M17L media was used for induction studies with the SP-04 strain) containing the appropriate antibiotics and grown to late log (OD_{650nm} = 0.6-0.7). 50 ml of culture was harvested by

centrifugation (10,000 X g) for 10 min and the cell pellets were resuspended in 25 ml PBS/azide (PBS + 0.02% sodium azide). The bacterial suspensions were placed in a 56°C water bath for 60 minutes to kill the cells. The cells were centrifuged and washed with 25 ml PBS/azide. The cell pellets were resuspended in 10 ml PBS/azide and the OD_{650nm} was adjusted to 1.0 with PBS/azide. 10 ml of adjusted suspension was centrifuged and 9 ml of supernatant was removed by pipet. The pellet was resuspended with the remaining supernatant. Strain preparations were stored at 4°C for up to 1 week. The resulting cell suspensions were used to compete for the binding of mAb 10F5 to recombinant M6 protein in competition ELISAs, as described by Jones et al (4, 5).

[0044] Southern blot analysis. Gene-specific probes were obtained after appropriate digestion of DNA from plasmids pCR2.1:635 (635 probe, 1153 bp), pLacG (LacG probe, 1791 bp) and p635:M/aphIII (M/aphIII probe, 2702 bp). DNA probes were gel isolated, cleaned and labeled with the Redivue 32P dCTP rediprime II random prime labeling system (Amersham). Chromosomal DNA from V288 and SP-02 was digested with ClaI/SmaI and DNA from V288 and SP-04 was digested with SmaI/XbaI. DNA fragments were separated on a 0.7% agarose gel and transferred to Zeta-Probe GT Genomic blotting membranes (BIO-RAD) by capillary transfer. Membranes were hybridized to specific DNA probes labeled with 32P as described above. Hybridization conditions were as recommended by the manufacturer. Blots were exposed to X-OMAT AR film (Kodak) at -70°C for 1 hour and developed in a HOPE Micro-Max developer.

[0045] Results

[0046] Construction of an intergenic mutant. Genomic analysis of recombinant *S. gordonii* GP1223 and the parent V288 strain revealed that the inserted foreign sequences (recombined into GP1223 chromosome) were being driven by a promoter normally located in front of two unknown open reading frames, orf A and orf B, which are just downstream of the

leucine operon (3). A NdeI site was introduced between orf A and orf B in p635 (Fig. 1) to serve as an insertion site between the two genes. First, an erythromycin gene was inserted and the resulting plasmid p635:ermC was transformed into V288. Since p635:ermC has no gram-positive origin of replication it cannot replicate in *S. gordonii* and was forced to integrate into the chromosome via homologous recombination and yielded erythromycin resistant colonies. PCR analysis of this double cross-over mutant 635/ermC with the primer pair CF43-CF45 produced a product that was 1.2 kb larger than wild type V288 due to insertion of the erythromycin gene.

[0047] The emm6 (12) gene fused to the aphIII gene (M/aphIII) was then inserted into p635 at the engineered NdeI site and the resulting plasmid p635:M/aphIII was transformed into V288 yielding kanamycin resistant colonies. This recombinant, SP-02, containing the M/aphIII fusion between orf A and orf B was verified by PCR using the primer pair CF43-CF45. SP-02 produced a product that was 2.7 kb larger than wild type V288 due to insertion of the M/aphIII cassette (data not shown). Southern blot analysis on SP-02 genomic DNA, restricted with ClaI and SmaI, using a portion of the 635 sequence and the M/aphIII sequence as labeled probes showed an intergenic insertion event had occurred. The 635 probe reacted with a 4.7 kb band in V288 (also restricted with ClaI and SmaI) and a 7.5 kb band in SP-02 which is a difference of 2.7 kb, the size of the insert (Fig. 3B), suggesting that it is a double cross-over mutant. The M/aphIII probe did not react with V288 DNA, which does not have the M/aphIII gene, and reacted with a 7.5 kb band in SP-02 as expected (Fig. 3C). M6 surface protein expression was demonstrated in SP-02 by streak blot (data not shown), and competition ELISA (Fig. 5A). The ELISA showed that the expression levels of SP-02 were about 3 fold lower than that of GP1223, which has the M protein gene inserted directly behind the promoter. Wild type strain V288 was used as a negative control in the competition ELISAs. The expected size of the M6 protein (28 KDa) was verified by western blot.

[0048] **Identification of the LacG operon in *S. gordonii*.** In *Lactococcus*

lactis the catabolism of lactose is initiated by a phosphoenolpyruvate-dependent phosphotransferase system. The genes that encode the phospho- β -galactosidase (lacG), the lactose-specific components of the phosphotransferase system (lacE and lacF) and the tagatose 6-phosphate pathway enzymes (lacA, lacB, lacC and lacD) are located in the same operon and are transcribed from the same promoter (Fig. 2B) (8,20). This same operon configuration has been found in *S. mutans* (15). Based on a homology search between the *S. mutans* lac operon sequence and the *S. pyogenes* sequence database (14), a similar operon was found in *S. pyogenes*. Primers TB85 and TB86 were designed to the most highly conserved regions within the lacG gene. These primers produced a 958 bp PCR product from the *S. gordonii* genomic DNA (Fig. 2A) that was approximately 80% identical to the lacG sequence from both *S. mutans* and *S. pyogenes*. Chromosomal walks in the *S. gordonii* chromosome produced a portion of the lacE gene upstream and the rest of the lacG gene downstream. The C-terminal end of the lacE gene and most of the lacG gene were cloned into pCR2.1 and an NdeI site was incorporated between amino acids 94 and 95 of lacG creating pLacG (Fig. 2A).

[0049] Construction of an intragenic LacG mutant. It was established by Payne et al (8) that foreign genes could be inserted into the lacG gene or for chromosomal expression. This intragenic insertion event inactivates the lacG gene, but has no obvious deleterious effects on the lac phenotype of the derived recombinant. The ability to insertionally inactivate the lacG gene is thought to be possible because there is a separate enzyme present in the strain that has secondary phospho- β -galactosidase activity (8, 19). The lac operon promoter has been used for controlled expression for chromosomally integrated genes (8). The pLacG plasmid serves as a way to insert genes into the chromosome of *S. gordonii* within the lacG gene. First the erythromycin gene was inserted at NdeI and the resulting plasmid pLacG:ermC was transformed into *S. gordonii* V288. Chromosomal insertion of an erythromycin resistant transformant was verified by PCR using the

primer pair TB107-TB96 (data not shown) and produced a product that was 1.2 Kb larger than wild type due to insertion of the erythromycin gene. This mutant was called LacG:ermC.

[0050] Next, the M/aphIII fusion cassette was inserted into pLacG to yield plasmid pLacG:M/aphIII. *S. gordonii* V288 was transformed with pLacG:M/aphIII and transformants were selected on BHI containing kanamycin. The resulting double cross-over LacG knockout mutant SP-04 (Fig. 2B) was verified by PCR using the primer pair TB107-TB96 and produced a product that was 2.7 kb larger than the wild type product due to insertion of the M/aphIII cassette (data not shown). SP-04 genomic DNA restricted with SmaI and XbaI was also verified by southern blot analysis using a lacE/G labeled probe and a M/aphIII labeled probe. The lacE/G probe reacted with a 1.3 kb band and a 7 kb band in V288 (also restricted with SmaI and XbaI) and three bands (1.2 kb, 3.1 kb, and 7 kb) in SP-04 as expected for a double cross over mutant in this locus (Fig. 4B). The M/aphIII probe did not react with V288 since it does not contain the M/aphIII fusion and it reacted with a 3.1 kb band in SP-04 as expected for insertion into the lacG gene (Fig. 4C). To verify that the M6 protein was expressed on the surface of SP-04, a streak blot was performed on colonies lifted from a BHI plate (data not shown), and a competition ELISA was performed using anti-M6 monoclonal antibodies (Fig. 5A). Wild type strain V288 was used as a negative control in the competition ELISA's. The results of the ELISA showed that the anti-M6 antibody reacted with cell surface-expressed M6 protein of SP-04 (Fig. 5A) at a lower level than GP1223. M6 protein expression from SP-04 was about 4 fold below GP1223 and SP-02 was about 3 fold lower than SP-04 (Fig. 5A). Expression of the lactose operon has been shown to be under the control of a regulator protein produced by the divergently transcribed lacR gene (8). With SP-04, a 4 fold increase in the level of M6 expression was obtained when cells were grown in the presence of lactose (M17L) compared to glucose (M17G) (Fig. 5B). Western blot analysis of supernatant from SP-04 showed the correct 28 KDa band.

[0051] EXAMPLE 2: Genomic Organization of Recombinant *Streptococcus gordonii* Strain Expressing the C-repeat Region of *Streptococcus pyogenes* M6 Protein

[0052] MATERIALS AND METHODS

[0053] Bacterial strains, plasmids, and oligonucleotides. The bacterial strains, plasmids, and oligonucleotides used or relevant to this study are listed in TABLE 2. *Escherichia coli* strains were grown in Luria-Bertani broth and *S. gordonii* strains in brain heart infusion broth (BHI; Difco Laboratories, Detroit, MI). All bacterial cultures were incubated at 37°C. Kanamycin (500 mg/ml) and streptomycin (500 mg/ml) were used whenever required for *S. gordonii* strains and ampicillin (50 mg/ml) for the selection and growth of *E. coli* strain INVαF' containing the plasmid pCR2.1 clones. The oligonucleotides, described in TABLE 1 were synthesized by either the Central Services Laboratory (Oregon State University) or Gibco-BRL Laboratories.

[0054] TABLE 2. Bacterial strains, plasmids, and oligonucleotides

Strain, plasmid, or oligonucleotide	Relevant markers and characteristics	Reference or source
Strains		
<i>E. coli</i>		
INVαF'	F' <i>endA1 recA1 hsdR17</i> (r _k ⁻ , m _k ⁺) <i>supE44 thi-1 gyrA96 relA1</i> ö80 <i>lacZ</i> ÄM15 Ä(<i>lacZYA-argF</i>)U169	Invitrogen
<i>S. gordonii</i> Challis		
V288	Wild-type (ATCC 35105)	ATCC

Strain, plasmid, or oligonucleotide	Relevant markers and characteristics	Reference or source
GP204	Spontaneous Sm ^r mutant of V288	Pozzi et al., 1988
GP230	Recombinant strain contains the <i>emm6</i> gene (<i>S. pyogenes</i>) and an <i>ermC</i> gene, Em ^r , parent strain (V288)	Pozzi et al., 1992
GP251	Recombinant recipient strain contains the cat gene flanked by 145 bp of <i>emm6</i> gene and 202 bp of <i>ermC</i> gene, Cm ^r , parent strain (GP230)	Oggioni et al., 1996
GP1214	Recombinant strain that expresses M6 protein (<i>S. pyogenes</i>) residues 1 to 16 fused to residues 222-441 and contains an <i>ermC</i> gene, Em ^r , parent strain (GP251)	Oggioni et al, 1994
GP1218	Recombinant strain that expresses M6 protein (<i>S. pyogenes</i>) residues 1 to 16 fused to residues 222-441 and contains an <i>aphIII</i> gene, Km ^r , parent strain (GP1214)	Oggioni et al, 1994
GP1223	Recombinant strain that expresses M6 protein (<i>S. pyogenes</i>) residues 1 to 16 fused to residues 222-441 and contains an <i>aphIII</i> gene, Km ^r , and has been converted to Sm ^r , parent strain (GP1218)	Oggioni et al, 1994
Plasmids		
pCR2.1	Km ^r , Amp ^r	Invitrogen
pSMB104	Contains the sequences encoding the CRR of M6 protein (<i>S. pyogenes</i>) residues 1 to 16 fused to residues 222-441 in tandem with an MspI/ClaI fragment of pE194 () encoding <i>ermC</i> cloned into pBluescript SK-.	Oggioni et al, 1994

Strain, plasmid, or oligonucleotide	Relevant markers and characteristics	Reference or source
Oligonucleotides		
CF4	5'-CTAATACGACTCACTATAGGGCTCGAGCG GCCGCCC GGGCAGGT-3'; Adaptor	Siebert et al, 1995
CF5	5'-GGATCCTAATACGACTCACTATAGGGC-3'; AP1	Siebert et al, 1995
CF6	5'-AATAGGGCTCGAGCGGC-3'; AP2, SEQ	Siebert et al, 1995
CF7	5'-ACCTGCCC-(C3-lcaa-CPG spacer); AP1	This study
CF8	5'-TCTAGAGGTACCTTCTCGTGCTTTGTCCGG -3';PCR (GP1223)	This study
CF9	5'-TACCGTCCCCCTAGGAAACACTCTTGAC- 3'; SEQ,PCR (GP1223)	This study
CF10	5'-TGACTTACTGGGGATCAAGCCTGATTGGG AG-3';PCR (GP1223)	This study
CF11	5'-AAGTACATCCGCAACTGTCCATACTCTGAT G-3'; PCR (GP1223)	This study
CF14	5'-GTTTTTCGTGTGCCTATTTTTTGTG-3', SEQ 1223	This study
CF15	5'-GAGCGCATCGAAAATGCTGTTG-3'; SEQ, PCR (GP204)	This study
CF16	5'-CTCAGTGTAAGAGGAAATCC-3'; SEQ	This study
CF17	5'-GAGTTTCAATGGTCTTGTCTGG-3'; SEQ, PCR (GP204, GP1223)	This study
CF18	5'-CTTGAAAAGCCTGAGGGCTGGTTAC-3'; SEQ, PCR (GP204)	This study
CF19	5'-CTTGACCTTTGGTACCTTTGAC-3'; SEQ	This study

Strain, plasmid, or oligonucleotide	Relevant markers and characteristics	Reference or source
CF20	5'-GATAGTCACACGGCTACTCACG-3'; SEQ	This study
CF21	5'-CGTGAGTAGCCGTGTGACTATC-3'; SEQ	This study
CF22	5'-GTCCATAGAGTTTGGATCCAAG-3'; SEQ	This study
CF23	5'-GTCAAAGGTACCAAAGGTCAAG-3'; SEQ	This study
CF24	5'-CCAGAAATTCGCGATATGAAC-3'; SEQ	This study
CF25	5'-GAATGAATCCAGATAAGGTGC-3'; SEQ	This study
CF26	5'-GATATCTTCAACTCATGGGATTAC-3'; SEQ, PCR (GP204)	This study
CF27	5'-CAAGATTCTCACCAGTTTTATG-3'; SEQ	This study
CF28	5'-GCTGCGATGCTTATGATTACC-3'; SEQ	This study
CF29	5'-GCTACCAATGCTGACAATAG-3'; SEQ	This study
CF31	5'-CCTAAGCAGTTTCTCAAGTTG-3'; SEQ	This study
CF32	5'-CATGTTGCCTATCGTCCAGC-3'; SEQ PCR (GP204, GP1223)	This study
CF35	5'-CGATTGACATAGAAATAAATTGGAG-3'; SEQ, PCR (GP204)	This study
CF36	5'-CTATAGTCAGTGTGGTTTAGACAAGC-3'; SEQ	This study
CF39	5'-GATTATGCTGAATCAAATAGTC-3', SEQ	This study
CF40	5'-GAGCACGATAGTAGTCAATCAC-3'; SEQ	This study
CF41	5'-CAATTTTTGACTGATACGATGGC-3'; SEQ	This study
CF42	5'-CTGTTCTTCCAACTTTTTCAGC-3'; SEQ	This study
CF43	5'-GTTTGGTGACCTATAGTCAGTG-3'; SEQ	This study

Strain, plasmid, or oligonucleotide	Relevant markers and characteristics	Reference or source
CF44	5'-ATCTATACATTCATGCCATCCA-3'; SEQ	This study
CF45	5'-TGGATGGCATGAATGTATAGAT-3'; SEQ	This study

[0055] Chromosomal walks. Chromosomal DNA was prepared from GP204 and GP1223 cells lysed with lysozyme and sodium dodecyl sulfate at pH 8.0 followed by three cycles of freezing and thawing and purified by phenol extraction. Chromosomal walks from a known region to an unknown region in uncloned genomic DNA were accomplished using an improved adaptor ligation PCR method (Siebert, P.D., et al. 1995. Nucl. Acids Res. 23:1087-1088).

[0056] Nucleotide sequence methods and analysis. PCR products of chromosomal walks were either sequenced directly or cloned into a TA-cloning vector pCR2.1 (Invitrogen) prior to sequence determination. Sequence determinations were performed at the Central Services Laboratory of the Center for Gene Research and Biotechnology (Oregon State University) using the dideoxy chain termination method. The M13 reverse sequencing primer and the T7 promoter primer were utilized to determine the sequence of PCR inserts cloned into pCR2.1, as well as the specifically designed primers listed in TABLE 2. Sequences were compiled and DNA and amino acid sequences were analyzed using programs developed by the Genetic Computer Group at the University of Wisconsin (Devereux, J., et al. 1984. Nucl. Acids. Res. 12:387-395). The BLAST programs (Altschul, S.F., et al. 1997 Nucl. Acids Res. 25:3389-3402) were used to compare the determined nucleotide sequences to the sequences in the GenBank databases.

[0057] Southern blot analysis. *S. gordonii* chromosomal DNA (1 µg),

purified as described above, was digested with restriction endonuclease EcoRV (New England Biolabs; Beverly, MA). DNA fragments were separated in 0.8% agarose-Tris-borate-EDTA and then transferred to Nytran Plus (Schleicher and Schuell; Keene, NH) membranes. Probe *P1 (including the C-terminal portion of orf2 and the promoter region) was derived by digestion with ClaI of the PCR product generated by PCR amplification with primers CF4 and CF9 from GP204 chromosomal template followed by the gel isolation of the 722-bp digestion product. Probe **P2 (encompassing the leuC and leuD ORFs) was obtained by digestion with ClaI of the PCR product generated by PCR amplification with primers CF4 and CF11 from a GP204 chromosomal template followed by the gel isolation of the 1894-bp digestion product. Probe ***P3 (a portion of C-repeat region of M6 protein of *S. pyogenes*) was obtained from by isolation of the 247-bp EcoRI/HindIII digestion product of pSMB104. The probes were labeled and hybridization products visualized using the Rad-Free Psoralin Biotin Probe Labeling and Hybridization Kit (Schleicher and Schuell; Keene, NH).

[0058] Isolation of total RNA and Northern blot analysis. *S. gordonii* total RNA was purified as previously described (Shaw, J.H., and D.B. Clewell. 1985. *J. Bacteriol.* 164:782-796). RNAs (10 mg) were separated in 1% (wt/vol) agarose -2.2 M formaldehyde gels and then transferred to NYTRAN MaxStrength (Schleicher and Schuell; Keene, NH) membranes. Probe *P1 (a portion of C-repeat region of M6 protein of *S. pyogenes*) was obtained from by isolation of the 247-bp EcoRI/HindIII digestion product of pSMB104. Probe *P2 (a portion of the leuB/leuC region of *S. gordonii*) by isolation of the 976-bp PCR product generated by PCR amplification with primers CF6 and CF18 from a GP204 chromosomal template. The probes were radiolabeled with [α -³²P]dCTP, using a random primers DNA labeling kit, Rediprime (Amersham; Piscataway, NJ) according to the manufactures instructions.

[0059] Nucleotide sequence accession numbers. The sequence of (this region) has been assigned GenBank accession nos AF251027, AF251028, and AF251029.

[0060] RESULTS

[0061] Chromosomal walks upstream and downstream of the GP1223 insert. To determine the chromosomal site of insertion of recombinant strains isolated from recipient *S. gordonii* strain GP251, a recombinant *S. gordonii* strain, GP1223, isolated by the targeted insertion of the coding sequence of the CRR of M6 protein of *S. pyogenes* into this site of GP251 was used as template for directed chromosomal walks upstream and downstream of the GP1223 insert. Chromosomal DNA from *S. gordonii* strain GP1223 was purified and a special adaptor, CF4 and CF7 (TABLE 2) was ligated to the ends of the DNA fragments generated by digestion of the chromosomal DNA with EcoRV. The adaptor-ligated DNA was used as template for primary and secondary PCR reactions using nested pairs of adaptor primers (CF5, CF6) and a nested pair of specific gene primers (CF8, CF9) to walk upstream of the *ClaI M6/aphIII insert or (CF10, CF11) to walk downstream of the insert (TABLE 2 and Figure 6A). The walk upstream of the insert yielded an 881-bp product designated "PCR walk 6-9" and the walk downstream, a 2175-bp product designated "PCR walk 6-11" as depicted in Figure 6A. The PCR walk products were sequenced directly commencing with primers CF6, CF9 and CF11, as applicable, and progressing with subsequently designed sequencing primers containing the sequences indicated in TABLE 1 and the positions and polarities illustrated in Figure 6.

[0062] The region upstream of the GP1223 insert contains regulatory signals. Immediately upstream of the GP1223 insert, sequences which conform to the consensus for promoters from gram-positive organisms (DeVos, W.M. 1987 FEMS Microbiol. Rev. 46:281-295; Graves, M.C., and

J.C. Rabinowitz. 1986. *J. Biol. Chem.* 261:11409-11415) were found. The alignment of the gram-positive promoter consensus with the sequence determined from "PCR walk 6-9" is shown in Figure 7A. This sequence shows the following features in common with the gram-positive promoter consensus: (i) the canonical -35 and -10 sequences; (ii) a spacing between those hexanucleotides of 16 to 18 nucleotides; (iii) the conserved dinucleotide sequence TG, immediately preceding the -10 sequence; and (iv) the AT-rich regions upstream of the -35 sequence (AT-box). Approximately 150 nucleotides upstream of the -35 region, a sequence containing dyad symmetry followed by a stretch of thymidine residues conforms to a prokaryotic factor-independent RNA polymerase terminator sequence (Figure 7B). Also, a region containing five direct repeats, 4 perfect and 1 imperfect, of 18 nucleotides (AGTTTAAAATCTTTATTC) was observed between the terminator and the promoter sequences (Figure 7B). Upstream of the terminator sequence, the nucleotide sequence of the 881-bp "PCR walk 6-9" also contained a partial ORF (designated ORF2, see Figure 6) encoding 169 residues with no apparent functional homologies in the databases at present. The sequence of ORF 2 had not terminated when the walk fragment ended at an EcoRV site to which the walking adaptor was ligated.

[0063] The region downstream of the GP1223 insert contains leuC and leuD homologues. Analysis of the nucleotide sequence of "PCR walk 6-11" (Figure 6A) revealed the presence of two partial ORFs encoding predicted proteins with significant homologies to the large subunit (leuC, pir S35134) and small subunit (leuD, pir E36889) of alpha-isopropylmalate isomerase (EC 4.2.1.33) of *Lactococcus lactis*, respectively. These gene products are involved in the biosynthesis of the branched-chain amino acids leucine, isoleucine and valine (Godon, J.J., et al. 1992. *J. Bacteriol.* 174:6580-6589). The ORF encoding the leuC homologue was partial in that it did not contain the initiation codon for the reading frame, but was open

from the start of the sequence at the *Clal* site. The partial *leuC* ORF of *S. gordonii* encoded 456 amino acid residues, whereas the complete *leuC* ORF of *L. lactis* is 460 residues in size. Nine nucleotides separate the termination codon of the *leuC* ORF and the initiation codon of the next ORF encoding the *leuD* homologue. The sequence of the *leuD* ORF was also partial because the ORF had not terminated when the walk fragment ended at an *EcoRV* site to which the walking adaptor was ligated. The partial *leuD* ORF of *S. gordonii* consisted of 172 residues as compared to the complete *leuD* ORF (191 residues) of *L. lactis*.

[0064] The *Clal* fragment flanking the GP1223 insert is duplicated. In order to corroborate and extend the structural organization deduced from the genomic walks described above, Southern blot analyses were carried out on chromosomal DNA from *S. gordonii* strains, GP204 and GP1223. Initially, chromosomal DNA was digested with restriction endonuclease *Clal*, electrophoretically separated fragments blotted to membranes and probed with radiolabeled DNA fragments obtained from "PCR walk 6-9" and "PCR walk 6-11" digested with *Clal*. Interestingly, both the probe specific for the upstream PCR walk (6-9) and the probe specific for the downstream PCR walk (6-11) hybridized to fragments that were indistinguishable in size (~ 3,000-bp) from both GP204 and GP1223 (data not shown). This result suggested that "PCR walk 6-9" and "PCR walk 6-11" might be contained within the same or a related DNA fragment. In order to determine if an internal *EcoRV* fragment linked the upstream (6-9) and downstream (6-11) PCR fragments on a single *Clal* fragment, PCR amplification with primers CF17 and CF32 was performed utilizing either GP204 or GP1223 chromosomal DNA as template. As predicted, a ~ 930-bp PCR amplification product was produced from both GP204 and GP1223 template DNA (Figure 6A and 6B) and the nucleotide sequence of these products was determined. The nucleotide sequence of the "PCR amp 17-32" product from both templates was identical and analysis revealed that they encoded the

remaining nine residues of the previously determined *leuD* ORF (for a total *leuD* ORF of 181 residues). After a gap of 144 nt, a predicted ORF contiguous with the partial ORF2 determined on the sequence of "PCR walk 6-9" added 90 amino acids to the previously determined partial ORF2 of 169 residues yielding a total size for ORF2 of 259 residues. Adding the internal 441-bp *EcoRV* fragment, revealed from the sequence analysis of "PCR amp 17-32", the proposed structure of the 3057-bp *Clal* fragment present as a single copy in GP204 and duplicated on either side of the M6 insertion site of GP1223 is depicted in Figure 8A. Corroboration of this proposed genomic structure is demonstrated by the Southern blot analyses shown in Figure 8B. The predicted *EcoRV* digestion products and hybridization profiles are in agreement with the proposed genomic structure illustrated in Figure 8A.

[0065] The region upstream of the *leuC* ORF contains *leuB* ORF.

Once the duplication of the *Clal* fragment containing the *leuC* and *leuD* ORFs was confirmed, it was of interest to determine the nucleotide sequence of the region of the chromosome immediately upstream of the *leuC* ORF from the parental strain, GP204. Genomic walks upstream of the *leuC* ORF on parental strain GP204 were performed using specific primer CF18, in combination with adaptor primers CF5, CF6 (Figure 6B). The resulting PCR product, walk 6-18 (976-bp), was cloned into pCR2.1 and the nucleotide sequence was determined. Analysis of this sequence for ORFs predicted it to encode a partial rightward reading ORF of 193 amino acid residues (Figure 6B).

[0066] Comparison of the leucine operon of *S. gordonii* to other organisms. Assembly and analysis of the complete nucleotide sequence of the duplicated *Clal* fragment flanking the recombination insertion site revealed ORF homology and structural organizational homology to the leucine operon of *Lactococcus lactis*, as well as numerous other gram-positive and gram-negative bacteria. Specifically, the predicted

products of translation of two of the three reading frames encoded in this fragment display significant homologies with the large subunit (leuC, pir S35134) and small subunit (leuD, pir E36889) of alpha-isopropylmalate isomerase (EC 4.2.1.33) of *Lactococcus lactis*. The *S. gordonii* reading frame with homology to leuC of *L. lactis* was 67% identical (207 identities over 307 residues) and 81% positive (250 positives over 307 residues).

[0067] Nucleotide sequence of the region downstream of the promoter of parental strain, GP204. In order to identify the gene(s) endogenously expressed by the promoter directing expression of the CRR insert of GP1223, genomic walks downstream of the promoter region on parental strain GP204 were performed using either specific primer CF15, CF26, or CF 35, respectively, in combination with adaptor primer CF6 (Figure 6B). The resulting PCR walks 6-15 (1637-bp), 6-26 (1409-bp) and 6-35 (1152-bp) were cloned into pCR2.1 and their nucleotide sequence was determined. The nucleotide sequence of all three PCR walks was identical from the regions in which the PCR products overlapped and downstream of the putative promoter were sequences that encoded two complete ORFs (designated ORF A and ORF B). ORF A and ORF B were predicted to encode polypeptides of 145 and 156 amino acid residues respectively. Homology searches of ORF A or ORF B against either the Non-redundant GenBank database () or the Unfinished Microbial genomes database () using the BLAST program were performed. ORF A bore homology over the C-terminal half of the predicted protein to the regulatory protein, SlyA, found in *Escherichia coli*, *Salmonella typhimurium* and other Enterobacteriaceae. The alignment of ORF A with SlyA(EC) contained 31% identities (23 identities over 74 residues) and 49% positives (37 positives over 74 residues). SlyA is a member of the MarR family of transcriptional regulators and a BLOCKS search () revealed ORF A to be a member of the MarR family as well. The search of the unfinished microbial genomes database revealed only one highly homologous predicted protein in the TIGR-1313

(sp12 contig) *Streptococcus pneumoniae* database that contained 85% residue identities (122 identities over 143 residues) and 90% positives (129 positives over 143 residues).

[0068] Similar searches with the predicted peptide sequence of ORF B revealed no known functional homologies or patterns. However, the search of the unfinished microbial genomes database also revealed only one highly homologous predicted protein in the TIGR-1313 *Streptococcus pneumoniae* database that contained 90% residue identities (140 identities over 155 residues) and 93% positives (145 positives over 155 residues). This ORF in the *S. pneumoniae* database was located in the same contig as the ORF A homologue described above (sp12) and the ORF B homologue was located immediately downstream of ORF A homologue revealing conservation in structural arrangement between the two subspecies as well.

[0069] While the invention has been described and illustrated herein by references to various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material, combinations of material, and procedures selected for that purpose. Numerous variations of such details can be implied and will be appreciated by those skilled in the art.